Grupo para la caracterización molecular de las neoplasias hematológicas
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (17)
2023
-
Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma
Cancers, Vol. 15, Núm. 2
-
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
The New England journal of medicine, Vol. 389, Núm. 11, pp. 1009-1022
2022
2021
-
Pathogenetic and prognostic implications of increased mitochondrial content in multiple myeloma
Cancers, Vol. 13, Núm. 13
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
2019
-
Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom € macroglobulinemia
Clinical Cancer Research, Vol. 25, Núm. 1, pp. 369-377
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
2017
-
Second primary malignancies in multiple myeloma: An overview and IMWG consensus
Annals of Oncology, Vol. 28, Núm. 2, pp. 228-245
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: A matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies
Annals of Hematology, Vol. 94, Núm. 8, pp. 1347-1356
-
Revised international staging system for multiple myeloma: A report from international myeloma working group
Journal of Clinical Oncology, Vol. 33, Núm. 26, pp. 2863-2869
2014
-
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy
Haematologica, Vol. 99, Núm. 6, pp. 1114-1122
-
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548
2013
2012
-
Management of treatment-emergent peripheral neuropathy in multiple myeloma
Leukemia, Vol. 26, Núm. 4, pp. 595-608
-
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Leukemia, Vol. 26, Núm. 1, pp. 149-157
2010
-
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma
Clinical Cancer Research, Vol. 16, Núm. 12, pp. 3260-3269